NEW YORK (GenomeWeb) – Illumina's second quarter revenues rose 21 percent year over year, the company announced after the close of the market on Tuesday, but fell short of Wall Street's consensus estimate on the top line.

The firm recognized total revenues of $539.4 million for the three months ended June 30, compared to $447.6 million in the second quarter 2014. Analysts, on average, had expected revenues of $541.8 million. On a constant currency basis, Illumina's revenues rose 25 percent.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In an against-all-odds twist, a researcher studying exceeding rare FOXG1 mutations discovers her daughter has the syndrome.

An effort by Genomics Medicine Ireland is creating a database of diseases based on the genomics of people in Ireland. It now is looking into the possibility of including Scotland in its work.

In recent weeks, the direct-to-consumer genetics firm has rolled out a health hub where customers can share information concerning 18 common health conditions.

In PLOS this week, new genes associated with prostate cancer risk, genetic patterns in M. bovis, and more.